Familial coexisting and colocalized psoriasis and vitiligo responding to alefacept

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue 3, 2009, Pages 172-175

  Al Mutairi, Nawaf ^a,b   Al Doukhi, Azari ^a  

^a FARWANIYA HOSPITAL   (Kuwait)

^b NONE   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CALCIPOTRIOL; KERATOLYTIC AGENT; STEROID;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CELL INFILTRATION; CLINICAL FEATURE; DEPIGMENTATION; DOSE RESPONSE; DRUG TREATMENT FAILURE; ERYTHEMA; FAMILIAL DISEASE; FEMALE; GRANULOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; LYMPHOCYTE; MALE; PARAKERATOSIS; PRIORITY JOURNAL; PSORIASIS; PUNCH BIOPSY; RECURRENT DISEASE; VITILIGO;

ADOLESCENT; BIOPSY; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; SKIN; TIME FACTORS; VITILIGO;

EID: 67651174631     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.08023     Document Type: Article

References (16)

1. Inamadar AC, Sampagavi VV, Athanikar SB, et al. Indian J Dermatol Venereol Leperol, 2001;67:214-5.
2. Menter A, Boyd AS, Silverman AH. Guttate psoriasis and vitiligo anatomic cohabitation. J Am Acad Dermatol 1989;20:698-700.
3. Banno T, Fujisaure H, Satomi H, et al. Psoriasis vulgaris and acute guttate psoriasis in a family. Int J Dermatol 2001;40:287-91.
4. Barker JNWN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001;26:321-5.
5. Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res 2007;20:271-8.
6. Al-Mutairi N, Zaki A, Sharma AK, et al. Cutaneous manifestations of diabetes mellitus. Med Prin Pract 2006;15:427-30.
7. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their relatives. Pigment Cell Res 2003;16:208-14.
8. Majumder PP, Norland JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993;129:994-8.
9. Sun X, Xu A, Wei X, et al. Genetic epidemiology of vitiligo, a study of 815 probands and their relatives from south China. Int J Dermatol 2006;45:1176-81.
10. Liu JB, Li M, Chen H, et al. Association of vitiligo with HLA-A2: a meta-analysis. J Eur Acad Dermatol Venereol 2007;21:205-13.
11. Al-Fouzan A, Al-Arbash M, Fouad F, et al. Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur J Immunogenet 1995;22:209-13.
12. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 2002;29:415-26.
13. Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004;8:14-9.
14. Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther 2007;20:270-6.
15. Fivenson D, Mathes B. Treatment of generalised lichen planus with alefacept. Arch Dermatol 2006;142:151-2.
16. Al-Fouzan AS, Habib MA, Sallam TH, et al. Detection of T lymphocytes and T lymphocyte subsets in lichen planus: in situ and in peripheral blood. Int J Dermatol 1996;35:426-9.